Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.

Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.

Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29.

PMID:
24048789
[PubMed - indexed for MEDLINE]
Free Article
2.

Patupilone in cancer treatment.

Bystricky B, Chau I.

Expert Opin Investig Drugs. 2011 Jan;20(1):107-17. doi: 10.1517/13543784.2011.542148. Epub 2010 Dec 11. Review.

PMID:
21142807
[PubMed - indexed for MEDLINE]
3.

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.

Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE.

Nat Med. 2010 Dec;16(12):1414-20. doi: 10.1038/nm.2236. Epub 2010 Nov 7.

PMID:
21057494
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement.

Whipple RA, Matrone MA, Cho EH, Balzer EM, Vitolo MI, Yoon JR, Ioffe OB, Tuttle KC, Yang J, Martin SS.

Cancer Res. 2010 Oct 15;70(20):8127-37. doi: 10.1158/0008-5472.CAN-09-4613. Epub 2010 Oct 5.

PMID:
20924103
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
[PubMed - indexed for MEDLINE]
6.

Improved endpoints for cancer immunotherapy trials.

Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J.

J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8. Review.

PMID:
20826737
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

PMID:
20823238
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

PMID:
20818862
[PubMed - indexed for MEDLINE]
Free Article
9.

Cabazitaxel.

Galsky MD, Dritselis A, Kirkpatrick P, Oh WK.

Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. No abstract available.

PMID:
20811375
[PubMed - indexed for MEDLINE]
10.

Abiraterone acetate is well tolerated without concomitant use of corticosteroids.

Attard G, Reid AH, de Bono JS.

J Clin Oncol. 2010 Oct 10;28(29):e560-1; author reply e562. doi: 10.1200/JCO.2010.29.5170. Epub 2010 Aug 30. No abstract available.

PMID:
20805462
[PubMed - indexed for MEDLINE]
Free Article
11.

Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P.

Cancer Res. 2010 Sep 1;70(17):6945-56. doi: 10.1158/0008-5472.CAN-10-0785. Epub 2010 Aug 10.

PMID:
20699369
[PubMed - indexed for MEDLINE]
Free Article
12.

Prostate cancer as a model for tumour immunotherapy.

Drake CG.

Nat Rev Immunol. 2010 Aug;10(8):580-93. doi: 10.1038/nri2817. Review.

PMID:
20651745
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR.

J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

PMID:
20644256
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

PMID:
20610543
[PubMed - indexed for MEDLINE]
Free Article
15.

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.

Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G.

BJU Int. 2011 Jan;107(2):234-9. doi: 10.1111/j.1464-410X.2010.09498.x.

PMID:
20590545
[PubMed - indexed for MEDLINE]
16.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

PMID:
20579941
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.

Gasent Blesa JM, Giner Marco V, Giner-Bosch V, Cerezuela Fuentes P, Alberola Candel V.

Am J Clin Oncol. 2011 Apr;34(2):155-9. doi: 10.1097/COC.0b013e3181d6b453.

PMID:
20539209
[PubMed - indexed for MEDLINE]
18.

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K.

Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17.

PMID:
20483588
[PubMed - indexed for MEDLINE]
19.

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM.

Urol Oncol. 2011 Nov-Dec;29(6):676-81. doi: 10.1016/j.urolonc.2009.12.023. Epub 2010 May 7.

PMID:
20451413
[PubMed - indexed for MEDLINE]
20.

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

Zhang J, Lu Y, Pienta KJ.

J Natl Cancer Inst. 2010 Apr 21;102(8):522-8. doi: 10.1093/jnci/djq044. Epub 2010 Mar 16. Review.

PMID:
20233997
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk